Tag Archives: Enablement

Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear

While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading

Posted in Enablement | Tagged , , | Leave a comment

AAM v. Neapco – Part III – The Dissent Faces a “Perfect Storm” of Conflated Doctrines

Since most of my last post discussing Judge Moore’s dissent focused on her criticism of the majority’s conclusion that the claimed invention—placing a tuned liner into a hollow “propshaft” to attenuate two modes of vibration—was directed to Hooke’s law and … Continue reading

Posted in Enablement | Tagged , , , | Leave a comment

The Unacknowledged Role of Section 112 in the Myriad Decisions

Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility  of “genomic DNA” of the arguable … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Edwards Lifesciences v. Corevalve – Pig Valve Implants Enabling

In Edwards Lifesciences AB v. Corevalve, Inc. (now a part of Medtronic), Appeal No. 2011-1215-1257 (Fed. Cir. Nov. 13, 2012), Corevalve challenged the validity of US Pat. No. 5,411,552 directed to a “transcather heart valve” on the basis that the … Continue reading

Posted in Enablement | Tagged , , , , , , , , | 1 Comment